









Markets
/
Stocks
/
nasdaq-mcrb
/

Seres Therapeutics Inc

MCRB

13.860USD

+1.160+9.13%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

121.48MMarket Cap

22.52P/E TTM



Seres Therapeutics Inc

13.860

+1.160+9.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Seres Therapeutics Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Seres Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

142 / 407

Overall Ranking

267 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

16.000

Target Price

+25.98%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Seres Therapeutics Inc Highlights

StrengthsRisks

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 42.86, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.30M shares, decreasing 49.82% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 292.10K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 8.20, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.20

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.73

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Seres Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.15, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 42.86, which is 2316.56% below the recent high of 1035.80 and 110.68% above the recent low of -4.58.

Score

Industry at a Glance

Previous score

6.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 142/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Seres Therapeutics Inc is 20.00, with a high of 22.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

16.000

Target Price

+25.98%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Seres Therapeutics Inc

MCRB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.09, which is lower than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 18.98 and the support level at 10.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.86

Change

0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.077

Sell

RSI(14)

31.766

Neutral

STOCH(KDJ)(9,3,3)

13.637

Neutral

ATR(14)

1.265

Low Volatility

CCI(14)

-129.017

Sell

Williams %R

81.755

Oversold

TRIX(12,20)

-0.946

Sell

StochRSI(14)

77.609

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

14.330

Sell

MA10

15.650

Sell

MA20

17.279

Sell

MA50

18.201

Sell

MA100

15.866

Sell

MA200

13.898

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 26.32%, representing a quarter-over-quarter decrease of 45.73%. The largest institutional shareholder is The Vanguard, holding a total of 292.10K shares, representing 3.34% of shares outstanding, with 1.73% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Flagship Ventures

1.16M

-0.00%

Nestle SA

1.09M

+186.83%

The Vanguard Group, Inc.

Star Investors

292.10K

-4.11%

Fidelity Management & Research Company LLC

267.07K

-75.56%

Bank Vontobel AG

80.33K

+47.93%

BlackRock Institutional Trust Company, N.A.

97.67K

+16.13%

Geode Capital Management, L.L.C.

91.60K

+13.17%

Marshall Wace LLP

91.41K

Charles Schwab Investment Management, Inc.

34.88K

-16.37%

State Street Investment Management (US)

26.83K

+7.17%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.38, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.